Several approaches targeting CD163+ pro-tumor macrophages and/or immune suppressive FoxP3+ have been associated with an improved response to immunotherapy and/or chemotherapy and are in pre-clinical or clinical development [53,54,55,56,57,58,59,60]. This evidence concerns the gene CD163 and neoplasm.